Overall tolerability and analgesic activity of intra-articular sodium hyaluronate in the treatment of knee osteoarthritis

被引:25
作者
Theiler, R [1 ]
Brühlmann, P
机构
[1] Triemli City Hosp, Rheumatol Clin, CH-8063 Zurich, Switzerland
[2] Triemli City Hosp, Inst Phys Med & Rehabil, CH-8063 Zurich, Switzerland
[3] Univ Zurich Hosp, Clin Rheumatol & Phys Med, CH-8091 Zurich, Switzerland
关键词
hyaluronic acid; intra-articular; knee osteoarthritis; sinovial; viscosupplementation;
D O I
10.1185/030079905X65547
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objective. Viscosupplementation with intra-articular hyaluronic acid (HA) is an alternative to the treatment of symptomatic knee osteoarthritis (OA) with pain relieving drugs. Sinovial*, is a sterile, non-pyrogenic 0.8% solution of highly purified sodium hyaluronate for intra-articular application. The aim of the present study was to investigate the safety and tolerability profile of this preparation in patients with symptomatic knee OA over 24 weeks. Research design and methods: This was a single group, open-label study, including outpatients of both sexes, aged between 18 and 85 years, with symptomatic knee OA. All patients underwent weekly intra-articular injections of HA for 5 consecutive weeks and were followed-up for 19 additional weeks. The safety and tolerability profile (primary endpoint) was assessed by adverse event (AE) reporting. The secondary endpoint was efficacy evaluated by changes in the Western Ontario and McMaster Universities (WOMAC) score vs. baseline. Patient and physician satisfaction were also recorded. Results: Intra-articular HA was generally well tolerated. The most frequent AE was pain at the injection site (5.8% of the injections); no serious treatment-related AE was reported. The WOMAC score was significantly reduced within the first 2 weeks of treatment (from 4.02 +/- 1.90 to 3.55 +/- 2.04, p = 0.0011), further decreased by the end of the injection series (week 6: 2.59 +/- 1.90; p < 0.0001) and maintained during the follow-up (week 24: 2.44 +/- 1.88; p < 0.0001). The WOMAC subscores were also significantly reduced from week 4 for 'pain' and from week 6 for 'stiffness' and 'physical function'. Conclusions: In the present study, intra-articular HA was well tolerated and safe in patients with symptomatic knee OA. Based on the sustained improvements in WOMAC score and subscores, a carry-over effect lasting for at least 19 weeks after the last injection may be proposed. These results further confirm the evidence of efficacy and safety of intra-articular HA in the management of knee OA.
引用
收藏
页码:1727 / 1733
页数:7
相关论文
共 22 条
[1]
Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee:: systematic review and meta-analysis [J].
Arrich, J ;
Piribauer, F ;
Mad, P ;
Schmid, D ;
Klaushofer, K ;
Müllner, M .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (08) :1039-1043
[2]
Balazs E A, 1968, Univ Mich Med Cent J, P255
[3]
Balazs E. A., 1982, DISORDERS KNEE, P61
[4]
BALAZS EA, 1989, CIBA F SYMP, V143, P265
[5]
BALAZS EA, 1993, J RHEUMATOL, V20, P3
[6]
HYALURONIC ACID IN SYNOVIAL FLUID .I. MOLECULAR PARAMETERS OF HYALURONIC ACID IN NORMAL AND ARTHRITIC HUMAN FLUIDS [J].
BALAZS, EA ;
WATSON, D ;
DUFF, IF ;
ROSEMAN, S .
ARTHRITIS AND RHEUMATISM, 1967, 10 (04) :357-&
[7]
Balazs EA, 1985, J EQUINE VET, V5, P217, DOI [DOI 10.1016/S0737, DOI 10.1016/S0737-0806(85)80102-7]
[8]
BALAZS EA, 1985, OSTEOARTHRITIS CURRE, P165
[9]
BELLAMY N, 2005, COCHRANE DATABASE SY
[10]
Berg P, 2004, CLIN EXP RHEUMATOL, V22, P300